Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine.
Splice-correcting phosphorothioate RNA antisense oligonucleotides with 2'-O-methyl modifications (ASO) are promising therapeutic agents for several disorders caused by aberrant splicing. However, their usefulness is hindered by the lack of efficient delivery. Unmodified 25 kDa polyethylenimine (PEI) has shown potential for plasmid delivery but seems to be less efficient for short nucleic acid sequences. Herein, we have evaluated several amino acid modified PEI molecules as carriers for ASO. By characterization of their properties, such as size, stability and transfection into mammalian cells, we have identified tyrosine-modified PEI (PEIY) as an efficient ASO delivery system. HeLa705 cells containing an aberrant luciferase gene, interrupted by a mutated beta-globin intron, were used to assess the splice correction effectiveness mediated by the various modified PEI/ASO polyplexes. PEIY has a self-assembly nature, as opposed to the highly cationic parent polymer, which is relevant for the stability of the PEIY/ASO complexes. As a result, at an optimal ratio of 20:1 (+/-), the complexes that formed significantly corrected the splicing on both the mRNA and the protein levels. ASO formulated with PEIY enhanced luciferase activity up to 450-fold. This increase was three times higher than that produced by the commercially available transfection agent Lipofectamine. PEIY/ASO polyplexes resulted in at least 80% correct splicing of the transcript. Moreover, extremely low doses of ASO (0.025 microM) showed significant splice correction represented by 150-fold increase of luciferase activity and 47% mRNA correction. Our findings suggest key parameters for formulating active complexes and reveal a new platform that can be further developed for ASO in vivo targeting.
Zaghloul
Eman M
EM
Department of Laboratory Medicine, Karolinska Institute, Sweden. Eman.Zaghloul@ki.se
Viola
Joana R
JR
Zuber
Guy
G
Smith
C I Edvard
CI
Lundin
Karin E
KE
D000596:Amino Acids / Q000737:chemistry*; D049109:Cell Proliferation / Q000187:drug effects; D006367:HeLa Cells; D006801:Humans; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008954:Models, Biological; D015394:Molecular Structure; D053758:Nanoparticles / Q000009:adverse effects / Q000737:chemistry; D016376:Oligonucleotides, Antisense / Q000009:adverse effects / Q000737:chemistry*; D010316:Particle Size; D011094:Polyethyleneimine / Q000009:adverse effects / Q000737:chemistry*
D000596:Amino Acids; D016376:Oligonucleotides, Antisense; D011094:Polyethyleneimine; D008156:Luciferases